Format

Send to

Choose Destination
Sci Transl Med. 2019 Jun 5;11(495). pii: eaav5341. doi: 10.1126/scitranslmed.aav5341.

Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis.

Author information

1
Nephrology Division, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
2
Nephrology Division, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
3
Nephrology Division, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China.
4
Nephrology Division, Shunde Hospital of Southern Medical University, Foshan 528300, China.
5
Institute of Human Virology and Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
6
Division of Gastrointestinal Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
7
Nephrology Division, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. pengh@mail.sysu.edu.cn zhaoyonh@bcm.edu.
8
Nephrology Division, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. pengh@mail.sysu.edu.cn zhaoyonh@bcm.edu.

Abstract

Progressive peritoneal fibrosis affects patients receiving peritoneal dialysis (PD) and has no reliable treatment. The mechanisms that initiate and sustain peritoneal fibrosis remain incompletely elucidated. To overcome these problems, we developed a strategy that prevents peritoneal fibrosis by suppressing PD-stimulated mesothelial-to-mesenchymal transition (MMT). We evaluated single-cell transcriptomes of mesothelial cells obtained from normal peritoneal biopsy and effluent from PD-treated patients. In cells undergoing MMT, we found cellular heterogeneity and intermediate transition states associated with up-regulation of enzymes involved in glycolysis. The expression of glycolytic enzymes was correlated with the development of MMT. Using gene expression profiling and metabolomics analyses, we confirmed that PD fluid induces metabolic reprogramming, characterized as hyperglycolysis, in mouse peritoneum. We found that transforming growth factor β1 (TGF-β1) can substitute for PD fluid to stimulate hyperglycolysis, suppressing mitochondrial respiration in mesothelial cells. Blockade of hyperglycolysis with 2-deoxyglucose (2-DG) inhibited TGF-β1-induced profibrotic cellular phenotype and peritoneal fibrosis in mice. We developed a triad of adeno-associated viruses that overexpressed microRNA-26a and microRNA-200a while inhibiting microRNA-21a to target hyperglycolysis and fibrotic signaling. Intraperitoneal injection of the viral triad inhibited the development of peritoneal fibrosis induced by PD fluid in mice. We conclude that hyperglycolysis is responsible for MMT and peritoneal fibrogenesis, and this aberrant metabolic state can be corrected by modulating microRNAs in the peritoneum. These results could provide a therapeutic strategy to combat peritoneal fibrosis.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center